Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
28
LQDA Quote, Financials, Valuation and Earnings
Last price:
$14.61
Seasonality move
:
-17.28%
Day range:
$14.10 - $14.67
52-week range:
$8.26 - $19.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
81.41x
P/B ratio:
24.40x
Volume:
1.6M
Avg. volume:
2.5M
1-year change:
10.6%
Market cap:
$1.2B
Revenue:
$14M
EPS (TTM):
-$1.58
Analysts' Opinion
-
Consensus RatingLiquidia has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $30.30, Liquidia has an estimated upside of 113.53% from its current price of $14.19.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $14.19.
Fair Value
-
According to the consensus of 7 analysts, Liquidia has 113.53% upside to fair value with a price target of $30.30 per share.
LQDA vs. S&P 500
-
Over the past 5 trading days, Liquidia has overperformed the S&P 500 by 5.2% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Liquidia does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Liquidia has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Liquidia reported revenues of $3.1M.
Earnings Growth
-
Liquidia has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Liquidia reported earnings per share of -$0.45.
Enterprise value:
1.2B
EV / Invested capital:
--
Price / LTM sales:
81.41x
EV / EBIT:
--
EV / Revenue:
83.72x
PEG ratio (5yr expected):
-0.80x
EV / Free cash flow:
-11.03x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$8.2M
Return On Assets:
-58.9%
Net Income Margin (TTM):
-903.8%
Return On Equity:
-165.38%
Return On Invested Capital:
-99.45%
Operating Margin:
-1135.42%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $16.9M | $16M | $14.1M | $3M | $3.1M | |
| Gross Profit | $14.1M | $12.3M | $8.2M | $1.5M | $1.6M | |
| Operating Income | -$33.5M | -$93M | -$127.9M | -$28.8M | -$35.4M | |
| EBITDA | -$30.6M | -$86.4M | -$111M | -$26.4M | -$33.2M | |
| Diluted EPS | -$0.56 | -$1.42 | -$1.58 | -$0.40 | -$0.45 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $55.1M | $62M | $99.7M | $167.9M | $177.2M | |
| Total Assets | $88.5M | $93.5M | $128.9M | $197.1M | $227.4M | |
| Current Liabilities | $7.9M | $8M | $6.8M | $21.9M | $60.5M | |
| Total Liabilities | $25.5M | $38.1M | $47.3M | $110.9M | $177.7M | |
| Total Equity | $62.9M | $55.4M | $81.6M | $86.3M | $49.7M | |
| Total Debt | $10.2M | $19.5M | -- | -- | $140.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$27.3M | -$58M | -$99.2M | -$24.9M | -$30.7M | |
| Cash From Investing | -$951K | -$11.5M | -$8.1M | -$624K | -$330K | |
| Cash From Financing | $64.8M | $133M | $119.3M | $99.7M | $24.3M | |
| Free Cash Flow | -$28.2M | -$69.5M | -$107.4M | -$25.5M | -$31M | |
LQDA
Sector
Market Cap
$1.2B
$34.4M
Price % of 52-Week High
73.11%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-6.57%
-1.01%
1-Year Price Total Return
10.6%
-37.36%
Beta (5-Year)
-0.012
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$13.77
200-day SMA
Buy
Level
$13.29
Bollinger Bands (100)
Sell
Level
13.2 - 16.28
Chaikin Money Flow
Buy
Level
8.4M
20-day SMA
Buy
Level
$13.29
Relative Strength Index (RSI14)
Buy
Level
52.31
ADX Line
Buy
Level
40.33
Williams %R
Neutral
Level
-25.4777
50-day SMA
Sell
Level
$15.01
MACD (12, 26)
Buy
Level
3.88
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
9.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.3785)
Sell
CA Score
(Annual)
Level (-4.1387)
Buy
Beneish M-Score
(Annual)
Level (-3.6111)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (4.4782)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Stock Forecast FAQ
In the current month, LQDA has received 6 Buy ratings 0 Hold ratings, and 1 Sell ratings. The LQDA average analyst price target in the past 3 months is $30.30.
-
Where Will Liquidia Stock Be In 1 Year?
According to analysts, the consensus estimate is that Liquidia share price will rise to $30.30 per share over the next 12 months.
-
What Do Analysts Say About Liquidia?
Analysts are divided on their view about Liquidia share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Liquidia is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Liquidia's Price Target?
The price target for Liquidia over the next 1-year time period is forecast to be $30.30 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 1 rates the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is LQDA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Liquidia is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LQDA?
You can purchase shares of Liquidia via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Liquidia shares.
-
What Is The Liquidia Share Price Today?
Liquidia was last trading at $14.61 per share. This represents the most recent stock quote for Liquidia. Yesterday, Liquidia closed at $14.19 per share.
-
How To Buy Liquidia Stock Online?
In order to purchase Liquidia stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
